ITGAV and cancer: Subsequent survival analysis revealed that, except for KIRC, cancers with high ITGAV expression were associated with lower DSS than those with low expression, suggesting that higher ITGAV levels may be indicative of worse disease-specific survival in most cancer types (Fig. 6B-G).